AlphAIalphai — Financial news for AI agents
globenewswire.comSEP 41 min read$TEVA

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

S&P Global Ratings upgraded Teva Pharmaceutical's long-term issuer credit rating to BBB- from BB+, reflecting strong financial performance and debt reduction. This is the third upgrade in recent months, with Teva now holding investment-grade ratings from all major agencies. The company's CFO attributed the upgrades to successful execution of its growth strategy and improved financial profile.

Original reporting
globenewswire.com
Published Sep 4, 2026, 3:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 4, 2026, 3:41 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$TEVA
Bullish
high confidence
Mentioned
$TEVA
Relevance
7/10
alphai data visualization · based on globenewswire.com
Decision brief

The 30-second read

$TEVABullishMed
01

Why it matters

The rating upgrade reflects successful execution of this strategy and may enhance financing flexibility.

02

Market read

First-report credit rating upgrade for a major pharma company, likely to influence bond yields and equity sentiment.

03

What to watch

Potential downside if underlying debt reduction targets are not met or if upcoming regulatory risks arise.

Relevance 7/10Novelty 7/10Timing: today

Background

Teva has been pursuing a 'Pivot to Growth' strategy, reducing debt and expanding its innovative pipeline.

Company-level read

Ticker impact

$TEVABullishHigh confidence
Context

S&P Global Ratings upgraded Teva's long-term credit rating to BBB- from BB+, indicating improved credit quality.

Expected impact

Potential modest upside as investors price in lower risk premium.

Evidence & confidence

Credit rating upgrades are typically viewed favorably by both bond and equity markets, especially for a company with high leverage.

Market effects

Sector

Improves outlook for the pharmaceutical sector's credit risk perception.

Regional

May boost Israeli market sentiment as a major pharma issuer gains investment-grade status.

Global

Adds to broader credit market optimism, especially for emerging market issuers.

Counterpoint

What could challenge this read

If the upgrade is already priced in, the move could be muted or lead to a short-cover rally.

Key entities

  • Company
    Teva Pharmaceutical Industries Ltd.

    Global pharmaceutical manufacturer.

  • Agency
    S&P Global Ratings

    Credit rating agency that issued the upgrade.

Read at source← All news

Related articles

SEP 4
$TEVAMed

Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

Teva Pharmaceuticals (TEVA) agreed to a stalking-horse bid of up to $125M for BioXcel Therapeutics' (BTAI) assets, including $57.5M in cash and up to $67.5M in contingent payments. The deal, subject to court approval, includes IGALMI and other assets. The FDA has a 2026 target date for a supplemental application to expand IGALMI's label to at-home use. Competing bids may arise.

finance.yahoo.com3 min
SEP 2
$TEVAMedAI 8/10

Teva Stock Drops As Celiac Trial Fails To Impress - TipRanks.com

Teva Pharmaceutical's (TEVA) stock declined despite early-stage positive results from a Phase 2a trial of TEV-408 for celiac disease. Investors were unimpressed due to the lack of later-stage data or a commercialization timeline. The company is focusing on specialty medicines and biosimilars to stabilize growth but faces challenges from debt and generic revenue pressure.

tipranks.com2 min
SEP 2
$TEVAMedAI 8/10

Teva Drug Rises to the Gluten Challenge, Stopping Intestinal Damage in Celiac Disease Trial

Teva Pharmaceutical Industries' experimental drug TEV-53408 met its main goal in a mid-stage trial, preventing intestinal damage in celiac disease patients. The Phase 2a study showed significant improvement in intestinal health and symptom scores compared to placebo. Teva plans further studies and projects peak sales of $1.5B-$2B for the drug, which targets the IL-15 pathway. The company has a deal with Royalty Pharma for up to $500M in support.

medcitynews.com2 min
SEP 2
$TEVAMedAI 8/10

Teva Reports Positive Phase 2a Results For TEV-408 In Celiac Disease

Teva Pharmaceutical (TEVA) reported positive Phase 2a trial results for TEV-408, an anti-IL-15 monoclonal antibody, in celiac disease. The study met its primary endpoint, showing significant prevention of gluten-induced intestinal damage. TEV-408 also reduced inflammation and improved patient-reported outcomes. The company plans to present further data and host an investor call. TEVA stock closed at $36.19, up 0.39%, and is up 0.77% in pre-market trading.

rttnews.com2 min
SEP 2
$TEVAMedAI 8/10

Teva Pharma Reports Positive Topline Results From Ongoing Phase 2a Study Of TEV 408

Teva Pharmaceutical (TEVA) reported positive topline results from a Phase 2a study of TEV 408, an anti-interleukin-15 monoclonal antibody, for treating celiac disease. The study met its primary endpoint, showing significant prevention of gluten-induced intestinal damage compared to placebo. The company plans to present further data at a future scientific meeting. TEVA shares rose 2.96% in pre-market trading.

rttnews.com1 min
SEP 2
$TEVAMedAI 9/10

Teva moves closer to a drug for celiac disease with positive Phase 2 results

Teva reported positive Phase 2a trial results for TEV-408, an experimental treatment for celiac disease. The trial met its primary endpoint, showing significant prevention of intestinal damage from gluten. Teva estimates potential annual revenue of $1 billion for the celiac indication if approved. The drug is also being developed for vitiligo, with a separate trial showing encouraging results. Teva could receive up to $500 million from Royalty Pharma for the vitiligo program.

calcalistech.com2 min